UK Cancer Immunotherapy Market Analysis

UK Cancer Immunotherapy Market Executive Analysis

The UK cancer immunotherapy market is at around $2.9 Bn in 2022 and is projected to reach $4.3 Bn in 2030, exhibiting a CAGR of 5.1% during the forecast period. NHS England receives the vast majority of The Department of Health and Social Care (DHSC) money. The National Health Service (NHS) receives $176 Bn (85%) of the funding for this fiscal year 2023 to 24. Additionally, funding is given to the Office for Health Improvement and Disparities, UK Health Security Agency, and Health Education England. The capital and income budgets for the NHS will not change from what was previewed in the previous autumn. Compared to commitments made in the Autumn 2022 Statement, there is a $0.3 Bn increase in health capital investment for 2023–24, although this is due to a budget underspend in 2022–23 and does not reflect an overall rise.

Just over 25% of all deaths in England occur from cancer on an annual basis.  134,802 persons in England passed away from cancer in 2021. Since 2001, more deaths have occurred—a 6% rise. However, the rate of cancer fatalities has decreased when taking into consideration the fact that England's population is ageing and rising at the same time. Between 2015 and 2019, more than 95% of patients with breast, prostate, or skin cancer survived for at least a year after their diagnosis. Less than 50% of those with pancreatic, lung, liver, oesophagal, lung, and stomach cancer lived for a full year after their diagnosis.

The power of the immune system is used by immunotherapy, a type of cancer treatment, to prevent, manage, and eradicate cancer. Immunology has already produced significant advances in the treatment of a number of diseases, from the preventive vaccine for cervical and liver cancer to the first medication ever demonstrated to lengthen the lives of patients with metastatic melanoma. But because every form of cancer is different, immunology and immunotherapy affect every malignancy in a different way. Keytruda is an immunotherapy that aids in the battle against cancer by stimulating the immune system. Keytruda can alter the way your immune system functions by causing it to attack healthy organs and tissues throughout your body. Sometimes, these issues might develop into grave or fatal issues and cause death. A form of immunotherapy called Keytruda prevents cancer cells from hiding by blocking the PD-1 pathway. Keytruda enables the immune system to identify and combat cancer cells, which is what it was designed to do.

Market Dynamics

Market Growth Drivers

Cancer is becoming more common over the world, particularly in the United Kingdom. As a result, there is now a larger demand for efficient cancer therapies, such as immunotherapies.  Recent years have seen tremendous advancements in the field of cancer immunotherapy, including the creation of novel medications and treatments. These scientific developments have increased the efficiency of cancer immunotherapy and broadened the spectrum of patient treatment options. Both the public and corporate sectors in the UK have made significant investments in the study and advancement of cancer immunotherapy. New medications and therapies that are less harmful and more successful than conventional cancer treatments have been developed as a result of this. Patients and medical professionals are becoming more aware of the potential advantages of cancer immunotherapy. The UK cancer immunotherapy market has grown as a result of the rise in demand for these treatments.

Market Restraints

Cancer immunotherapy medications and therapies can be costly, which may prevent some patients from accessing them. Due to cost concerns, consumers and healthcare professionals may be reluctant to accept these therapies, which could be a barrier to the UK cancer immunotherapy market's expansion.  While cancer immunotherapy has occasionally produced encouraging results, not all cancers or people may respond well to treatment. As a result, the market's growth may be constrained since patients and healthcare professionals may be reluctant to use therapies that are not very effective. Cancer immunotherapy is a potentially new kind of cancer treatment, but patients have other options as well. Immunotherapy may continue to face competition from more conventional cancer therapies including chemotherapy and radiation therapy.

Competitive Landscape

Key Players

• Adaptimmune (GBR)- Enhance T-cell treatments are created by Adaptimmune to help the immune system recognize and target cancer cells. Its SPEAR T cell technique is intriguing since it can target different solid tumours.
• Autolus Therapeutics (GBR)- Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) are used by Autolus Therapeutics to rewire T cells so they can identify and then destroy tumour cells.
• Crescendo Biologics (GBR)- A bispecific T-cell engager that targets the prostate-specific membrane antigen is the leading proprietary candidate from Crescendo Biologics. Within the tumour microenvironment, it can specifically activate T cells that are unique to the tumour. It is now moving closer to clinical development.
• Ervaxx (GBR)- Ervaxx recently made headlines when it acquired the rights for an innovative new universal cancer immunotherapy that is still in the preclinical stage.
• Immunocore (GBR)- The company's ImmTAC (immune mobilizing monoclonal TCRs against cancer) technology is based on a new class of bi-specific biologics that can cause cancer cells to mount a particular T cell response
• Amgen
• Bayer
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Pfizer
• Eli Lily

Healthcare Policies and Regulatory Landscape

The National Health Service (NHS) is primarily in charge of overseeing cancer health insurance and payment regulations in the UK. For qualified patients, the NHS covers cancer therapies, including immunotherapy. The effectiveness and financial efficiency of new cancer treatments are regularly evaluated by the NHS. Treatment may be authorized for coverage by the NHS if it is determined to be both efficient and affordable. Patients in the UK may be qualified for financial assistance programs or clinical trials in addition to insurance coverage, giving them access to cancer therapies like immunotherapy. These initiatives and trials might be supported by public bodies like the NHS or private businesses. The NHS uses a system of fixed prices for medications and medical services when it comes to reimbursement policies. Drug costs are negotiated between pharmaceutical firms and the NHS and are then set for a specific amount of time. Private insurance companies could have their own guidelines for cancer treatment reimbursement.